Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer

Lung Cancer

Volumn 108, Issue , 2017, Pages 75-82

  Hidaka, Noriko ^a   Iwama, Eiji ^a,b   Kubo, Naoki ^a,c   Harada, Taishi ^a   Miyawaki, Kohta ^a   Tanaka, Kentaro ^a   Okamoto, Isamu ^a   Baba, Eishi ^b   Akashi, Koichi ^a   Sasaki, Hiroyuki ^c   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Allele; Digital PCR; Epidermal growth factor receptor (EGFR); Lung cancer; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ALLELE; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; DRUG TREATMENT FAILURE; EGFR GENE; GENE MUTATION; HUMAN; HUMAN CELL; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; AMINO ACID SUBSTITUTION; DRUG RESISTANCE; EXON; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; TUMOR CELL LINE;

ALLELES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXONS; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85014916881     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.02.019     Document Type: Article

References (49)

1. [1] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., Fukuoka, M., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361:10 (2009), 947–957.
2. [2] Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362:25 (2010), 2380–2388.
3. [3] Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, M., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet. Oncology 11:2 (2010), 121–128.
4. [4] Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:8 (2011), 735–742.
5. [5] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:3 (2012), 239–246.
6. [6] Sequist, L.V., Yang, J.C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S.L., Orlov, S., Tsai, C.M., Boyer, M., Su, W.C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K.H., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31:27 (2013), 3327–3334.
7. [7] Wu, Y.L., Zhou, C., Hu, C.P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J.H., Lee, K.Y., Xu, C.R., Massey, D., Kim, M., Shi, Y., Geater, S.L., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15:2 (2014), 213–222.
8. [8] Mitsudomi, T., Yatabe, Y., Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:12 (2007), 1817–1824.
9. [9] Ohashi, K., Maruvka, Y.E., Michor, F., Pao, W., Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31:8 (2013), 1070–1080.
10. [10] Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.G., Halmos, B., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352:8 (2005), 786–792.
11. [11] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M., Engelman, J.A., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3(75), 2011, 75ra26.
12. [12] Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., Kris, M.G., Miller, V.A., Ladanyi, M., Riely, G.J., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19:8 (2013), 2240–2247.
13. [13] Kim, Y., Ko, J., Cui, Z., Abolhoda, A., Ahn, J.S., Ou, S.H., Ahn, M.J., Park, K., The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 11:3 (2012), 784–791.
14. [14] Wu, S.G., Liu, Y.N., Tsai, M.F., Chang, Y.L., Yu, C.J., Yang, P.C., Yang, J.C., Wen, Y.F., Shih, J.Y., The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 7:11 (2016), 12404–12413.
15. [15] Rosell, R., Molina, M.A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., Isla, D., Provencio, M., Cobo, M., Insa, A., Garcia-Campelo, R., Reguart, N., Majem, M., Viteri, S., Carcereny, E., Porta, R., Massuti, B., Queralt, C., de Aguirre, I., Sanchez, J.M., Sanchez-Ronco, M., Mate, J.L., Ariza, A., Benlloch, S., Sanchez, J.J., Bivona, T.G., Sawyers, C.L., Taron, M., Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 17:5 (2011), 1160–1168.
16. [16] Su, K.Y., Chen, H.Y., Li, K.C., Kuo, M.L., Yang, J.C., Chan, W.K., Ho, B.C., Chang, G.C., Shih, J.Y., Yu, S.L., Yang, P.C., Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30:4 (2012), 433–440.
17. [17] Fujita, Y., Suda, K., Kimura, H., Matsumoto, K., Arao, T., Nagai, T., Saijo, N., Yatabe, Y., Mitsudomi, T., Nishio, K., Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J. Thorac. Oncol. 7:11 (2012), 1640–1644.
18. [18] Costa, C., Molina, M.A., Drozdowskyj, A., Gimenez-Capitan, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., Majem, M., Felip, E., Carcereny, E., Garcia-Campelo, R., Viteri, S., Taron, M., Ono, M., Giannikopoulos, P., Bivona, T., Rosell, R., The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin. Cancer Res. 20:7 (2014), 2001–2010.
19. [19] Li, H., Hu, H., Wang, R., Pan, Y., Wang, L., Li, Y., Zhang, Y., Ye, T., Zhang, Y., Li, B., Shen, L., Sun, Y., Chen, H., Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. OncoTargets Ther. 7 (2014), 513–524.
20. [20] Yu, H.A., Arcila, M.E., Hellmann, M.D., Kris, M.G., Ladanyi, M., Riely, G.J., Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Annal. Oncol. 25:2 (2014), 423–428.
21. [21] Iwama, E., Takayama, K., Harada, T., Okamoto, I., Ookubo, F., Kishimoto, J., Baba, E., Oda, Y., Nakanishi, Y., Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget 6:24 (2015), 20466–20473.
22. [22] Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., Ichinose, Y., Takeuchi, Y., Sakamoto, K., Matsumura, A., Koh, Y., Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin. Cancer Res. 21:15 (2015), 3552–3560.
23. [23] Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., Kiura, K., Shimizu, N., Date, H., Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66:16 (2006), 7854–7858.
24. [24] Godin-Heymann, N., Bryant, I., Rivera, M.N., Ulkus, L., Bell, D.W., Riese, D.J., 2nd, J., Settleman, D.A., Haber, Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 67:15 (2007), 7319–7326.
25. [25] Chmielecki, J., Foo, J., Oxnard, G.R., Hutchinson, K., Ohashi, K., Somwar, R., Wang, L., Amato, K.R., Arcila, M., Sos, M.L., Socci, N.D., Viale, A., de Stanchina, E., Ginsberg, M.S., Thomas, R.K., Kris, M.G., Inoue, A., Ladanyi, M., Miller, V.A., Michor, F., Pao, W., Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med., 3(90), 2011, 90ra59.
26. [26] Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.E., Krishnamurthy Radhakrishna, V., Siravegna, G., Hu, H., Raoof, S., Lockerman, E., Kalsy, A., Lee, D., Keating, C.L., Ruddy, D.A., Damon, L.J., Crystal, A.S., Costa, C., Piotrowska, Z., Bardelli, A., Iafrate, A.J., Sadreyev, R.I., Stegmeier, F., Getz, G., Sequist, L.V., Faber, A.C., Engelman, J.A., Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22:3 (2016), 262–269.
27. [27] Ramirez, M., Rajaram, S., Steininger, R.J., Osipchuk, D., Roth, M.A., Morinishi, L.S., Evans, L., Ji, W., Hsu, C.H., Thurley, K., Wei, S., Zhou, A., Koduru, P.R., Posner, B.A., Wu, L.F., Altschuler, S.J., Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun., 7, 2016, 10690.
28. [28] Walter, A.O., Sjin, R.T., Haringsma, H.J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, P., Niu, D., Nacht, M., Petter, R.C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., Van Dyke, T., Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A.D., Harding, T.C., Allen, A., Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3:12 (2013), 1404–1415.
29. [29] Cross, D.A., Ashton, S.E., Ghiorghiu, S., Eberlein, C., Nebhan, C.A., Spitzler, P.J., Orme, J.P., Finlay, M.R., Ward, R.A., Mellor, M.J., Hughes, G., Rahi, A., Jacobs, V.N., Red Brewer, M., Ichihara, E., Sun, J., Jin, H., Ballard, P., Al-Kadhimi, K., Rowlinson, R., Klinowska, T., Richmond, G.H., Cantarini, M., Kim, D.W., Ranson, M.R., Pao, W., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4:9 (2014), 1046–1061.
30. [30] Janne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.J., Kim, S.W., Su, W.C., Horn, L., Haggstrom, D., Felip, E., Kim, J.H., Frewer, P., Cantarini, M., Brown, K.H., Dickinson, P.A., Ghiorghiu, S., Ranson, M., AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372:18 (2015), 1689–1699.
31. [31] Sequist, L.V., Soria, J.C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., Papadimitrakopoulou, V., Solomon, B.J., Oxnard, G.R., Dziadziuszko, R., Aisner, D.L., Doebele, R.C., Galasso, C., Garon, E.B., Heist, R.S., Logan, J., Neal, J.W., Mendenhall, M.A., Nichols, S., Piotrowska, Z., Wozniak, A.J., Raponi, M., Karlovich, C.A., Jaw-Tsai, S., Isaacson, J., Despain, D., Matheny, S.L., Rolfe, L., Allen, A.R., Camidge, D.R., Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372:18 (2015), 1700–1709.
32. [32] Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Janne, P.A., Oxnard, G.R., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21:6 (2015), 560–562.
33. [33] Yu, H.A., Tian, S.K., Drilon, A.E., et al. Acquired resistance of egfr-mutant lung cancer to a t790m-specific egfr inhibitor: emergence of a third mutation (c797s) in the egfr tyrosine kinase domain. JAMA Oncol. 1:7 (2015), 982–984.
34. [34] Ercan, D., Choi, H.G., Yun, C.H., Capelletti, M., Xie, T., Eck, M.J., Gray, N.S., Janne, P.A., EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin. Cancer Res. 21:17 (2015), 3913–3923.
35. [35] Leone, A., Highly sensitive detection of EGFR T790M mutation in pre-TKI specimens of EGFR-mutated NSCLC: in cis, in trans, or a different clone?. J. Thorac. Oncol. 8:3 (2013), e26–e27.
36. [36] Yung, T.K., Chan, K.C., Mok, T.S., Tong, J., To, K.F., Lo, Y.M., Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin. Cancer Res. 15:6 (2009), 2076–2084.
37. [37] Shien, K., Toyooka, S., Yamamoto, H., Soh, J., Jida, M., Thu, K.L., Hashida, S., Maki, Y., Ichihara, E., Asano, H., Tsukuda, K., Takigawa, N., Kiura, K., Gazdar, A.F., Lam, W.L., Miyoshi, S., Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73:10 (2013), 3051–3061.
38. [38] Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., Mitsudomi, T., Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12:19 (2006), 5764–5769.
39. [39] Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., Varmus, H., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2(3), 2005, e73.
40. [40] Miyazawa, H., Tanaka, T., Nagai, Y., Matsuoka, M., Sutani, A., Udagawa, K., Zhang, J., Hirama, T., Murayama, Y., Koyama, N., Ikebuchi, K., Nagata, M., Kanazawa, M., Nukiwa, T., Takenoshita, S., Kobayashi, K., Hagiwara, K., Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 99:3 (2008), 595–600.
41. [41] Shi, Y., Au, J.S., Thongprasert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., Heeroma, K., Itoh, Y., Cornelio, G., Yang, P.C., A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9:2 (2014), 154–162.
42. [42] Girard, N., Lou, E., Azzoli, C.G., Reddy, R., Robson, M., Harlan, M., Orlow, I., Yatabe, Y., Nafa, K., Ladanyi, M., Viale, A., Kris, M.G., Riely, G., Miller, V., Klein, R.J., Matsuo, K., Pao, W., Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin. Cancer Res. 16:2 (2010), 755–763.
43. [43] Bell, D.W., Gore, I., Okimoto, R.A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S.V., Brannigan, B.W., Mohapatra, G., Settleman, J., Haber, D.A., Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37:12 (2005), 1315–1316.
44. [44] Mulloy, R., Ferrand, A., Kim, Y., Sordella, R., Bell, D.W., Haber, D.A., Anderson, K.S., Settleman, J., Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67:5 (2007), 2325–2330.
45. [45] Yun, C.H., Mengwasser, K.E., Toms, A.V., Woo, M.S., Greulich, H., Wong, K.K., Meyerson, M., Eck, M.J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 105:6 (2008), 2070–2075.
46. [46] Niederst, M.J., Hu, H., Mulvey, H.E., Lockerman, E.L., Garcia, A.R., Piotrowska, Z., Sequist, L.V., Engelman, J.A., The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21:17 (2015), 3924–3933.
47. [47] Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32:6 (2014), 579–586.
48. [48] Sacher, A.G., Paweletz, C., Dahlberg, S.E., Alden, R.S., O'Connell, A., Feeney, N., Mach, S.L., Janne, P.A., Oxnard, G.R., Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2:8 (2016), 1014–1022.
49. [49] Paweletz, C.P., Sacher, A.G., Raymond, C.K., Alden, R.S., O'Connell, A., Mach, S.L., Kuang, Y., Gandhi, L., Kirschmeier, P., English, J.M., Lim, L.P., Janne, P.A., Oxnard, G.R., Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin. Cancer Res. 22:4 (2016), 915–922.